04th week of 2009 patent applcation highlights part 42 |
Patent application number | Title | Published |
20090023719 | PYRIMIDINE DERIVATIVES 934 - A compound of formula (I) | 2009-01-22 |
20090023720 | 2-Amino 1H-Imidazo Ring Systems and Methods - 1H-Imidazo ring systems (e.g., imidazopyridines, imidazoquinolines, imidazonaphthyridines, 6,7,8,9-tetrahydro imidazoquinolines and imidazonaphthyridines) with an amino substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 2009-01-22 |
20090023721 | Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament - This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT | 2009-01-22 |
20090023722 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES - Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases. | 2009-01-22 |
20090023723 | Purinone derivatives for treating neurodegenerative diseases - The invention relates to purinone derivatives useful in treating disorders that are mediated by adenosine receptor function, including neurodegenerative diseases and inflammation. The compounds are of the general formula: | 2009-01-22 |
20090023724 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith - Provided herein are Heteroaryl Compounds having the following structure: | 2009-01-22 |
20090023725 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors - Compounds of formula (I): | 2009-01-22 |
20090023726 | Heterocyclylalkyl Derivatives as Novel Inhibitors of Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 2009-01-22 |
20090023727 | PHTHALAZINONE DERIVATIVES - A compound of the formula (I): | 2009-01-22 |
20090023728 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof - Compounds of general formula (I) wherein D, E, R | 2009-01-22 |
20090023729 | Trisubstituted amine compound - The present invention relates to a compound of the general formula (1): | 2009-01-22 |
20090023730 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION - The invention provides compounds and pharmaceutically acceptable salts of Formula I | 2009-01-22 |
20090023731 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases. | 2009-01-22 |
20090023732 | Citrate Salt of an Indole Derivative and its Pharmaceutical Use - The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders. | 2009-01-22 |
20090023733 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them - The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state. | 2009-01-22 |
20090023734 | INHIBITORS OF HISTONE DEACETYLASE - The invention provides compounds and methods for treating cell proliferative diseases. The invention provides new inhibitors of histone deacetylase enzymatic activity, compositions of the compounds comprising the inhibitors and a pharmaceutically acceptable carrier, excipient, or diluent, and methods of using the compounds to inhibit cellular proliferation in vitro and therapeutically. | 2009-01-22 |
20090023735 | Sulphonamide Derivatives - The invention relates to sulphonamide derivatives of formula (I), where R | 2009-01-22 |
20090023736 | Compounds for treating proliferative disorders - Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. | 2009-01-22 |
20090023737 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands - Compounds of the Formula: | 2009-01-22 |
20090023738 | DIAMINOPYRIMIDINES AS MODULATORS OF THE EP2 RECEPTOR - The present invention relates to diaminopyrimidines of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP | 2009-01-22 |
20090023739 | CAPASE INHIBITORS AND USES THEREOF - This invention provides novel caspase inhibitors of formula I: | 2009-01-22 |
20090023740 | SODIUM CHANNEL INHIBITORS - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel. | 2009-01-22 |
20090023741 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR - The present invention relates to aryl/hetarylamide derivatives of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP | 2009-01-22 |
20090023742 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones. | 2009-01-22 |
20090023743 | INHIBITORS OF PROTEIN KINASES - Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. | 2009-01-22 |
20090023744 | COMBINATION THERAPY FOR DEPRESSION - A combination therapy for treating depressive disorders is provided herein. The combination therapy comprises administering an effective amount of bupropion or its metabolites together with at least one serotonin 5-HT | 2009-01-22 |
20090023745 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors - Substituted pyrazolo[4,3-c]pyridine derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer. | 2009-01-22 |
20090023746 | COMPOUNDS AND THEIR USES 707 - The present invention relates to isoquinolinone derivatives of formula (I): | 2009-01-22 |
20090023747 | Cysteine Protease Inhibitors - A compound of the formula (II) wherein one of R | 2009-01-22 |
20090023748 | Cysteine Protease Inhibitors - Compounds of the formula II: | 2009-01-22 |
20090023749 | POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL)BUTYL-4-(2- -CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE - The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation. | 2009-01-22 |
20090023750 | NOVEL SALTS OF PIPERAZINE COMPOUNDS AS D3/D2 ANTAGONISTS - The present invention relates to novel monohydrochloride, dihydrochloride, monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or their hydrates and/or solvates. Moreover, the invention relates to the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require modulation of dopamine receptor and to pharmaceutical compositions containing them. | 2009-01-22 |
20090023751 | COMPOUNDS THAT PROTECT AGAINST SENSORY HAIR CELL DEATH - The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects. | 2009-01-22 |
20090023752 | N-Heterocyclylphthaldiamides as Insecticides - New N-heterocyclylphthaldiamides of structure (I) | 2009-01-22 |
20090023753 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents - This invention relates to novel 1,3-thiazole-5-carboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents. | 2009-01-22 |
20090023754 | Modified release famciclovir pharmaceutical compositions - A modified release pharmaceutical composition of famciclovir contains at least 60% by weight famciclovir with at least 5% by weight of a release retardant. Particularly useful as a release retardant include polymers, especially a mixture of polyvinyl acetate and polyvinylpyrrolidone. A method of making such pharmaceutical compositions using a extruder and a granulation method is particularly useful. | 2009-01-22 |
20090023755 | USE OF ISTRADEFYLLINE FOR TREATING BEHAVIORAL DISORDERS - The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like. | 2009-01-22 |
20090023756 | SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS - The invention pertains to substituted quinazoline compounds of structures (I) and (II) that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom. (I, II). | 2009-01-22 |
20090023757 | PROCESS FOR PREPARING BICYCLIC COMPOUNDS - The present invention relates to a novel process for preparing compounds of formula (IA), which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors, from intermediate compounds of formula (I), by a coupling reaction catalysed by copper. | 2009-01-22 |
20090023758 | Macrocyclic Inhibitors of Hepatitis C Virus - Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR | 2009-01-22 |
20090023759 | Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase - A quinazoline derivative of the Formula I: | 2009-01-22 |
20090023760 | Anti-cancer cyclopenta[G]quinazoline compounds - Cyclopenta[g]quinazolines of the formula (I): wherein: A is a group OR or NR | 2009-01-22 |
20090023761 | Heterocyclic compounds and their uses - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2009-01-22 |
20090023762 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies - This invention relates to novel compounds having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel en compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia. | 2009-01-22 |
20090023763 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists - New antagonists of the A | 2009-01-22 |
20090023764 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C - A pyrimidinedione derivative of formula (I) or a pharmaceutically acceptable salt thereof exhibits excellent inhibitory activity against hepatitis C virus. | 2009-01-22 |
20090023765 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described. | 2009-01-22 |
20090023766 | Pharmaceutical formulation of apomorphine for buccal administration - The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function. | 2009-01-22 |
20090023767 | Inhibitors of Checkpoint Kinases - The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer. | 2009-01-22 |
20090023768 | RAPAMYCIN DERIVATIVES FOR TREATING NEUROBLASTOMA - A rapamycin derivative for use in the treatment of neuroblastome, optionally in combination with a second drug substance. | 2009-01-22 |
20090023769 | Organic Compounds - Compounds of formula I | 2009-01-22 |
20090023770 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them - The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives. | 2009-01-22 |
20090023771 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTON PUMP INHIBITOR AND PROTEIN COMPONENT - The present disclosure relates to, inter alia, pharmaceutical compositions comprising a H | 2009-01-22 |
20090023772 | Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors - This invention relates to novel substituted heteroaryloxy alkylamines useful as monoamine neurotransmitter re-uptake inhibitors. | 2009-01-22 |
20090023773 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS - Disclosed are compounds that modulate the activity of the gated ion channels. Compounds that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pain, inflammation, the neurological system, the gastrointestinal system and genitourinary system. Preferred compounds include compounds of the Formulae 1, 2, 3, 4, and 5. | 2009-01-22 |
20090023774 | Pyridine analogs as C5A antagonists - The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them. | 2009-01-22 |
20090023775 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1 -YL )-ETHYL]-3-(2-METHYL-QUINOLIN- 4-YL)- UREA AS CRYSTALLINE SULFATE SALT - The invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt alone or in combination with other compounds. Further, the present invention relates to formulations of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt in the preparation of pharmaceutical compositions. The invention also relates to the use of such sulfate salts in formulations as neurohormonal antagonists. | 2009-01-22 |
20090023776 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTIESTROGEN AGENTS - The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antiestrogen agent for inhibiting the growth of tumor cells, useful in the treatment of cancer. | 2009-01-22 |
20090023777 | Substituted 4-amino-benzylpiperidine compounds - This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds. | 2009-01-22 |
20090023778 | Composition Containing Anti-Dementia Drug - An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition. According to the present invention, there is provided a composition containing at least two kinds of anti-dementia drugs; such a composition containing at least one sustained-release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist. | 2009-01-22 |
20090023779 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents - The present invention relates to compounds of formula (I): | 2009-01-22 |
20090023780 | Therapeutic use of a derivative of thienylcyclohexylamine - The invention concerns the use of a thienylcyclohexylamine, on its own or associated with other substances with pharmaceutical activity, for preparing a medicine designed to prevent and/or treat pain and/or nociception. | 2009-01-22 |
20090023781 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors - The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. | 2009-01-22 |
20090023782 | INCREASING PLANT VIGOR - Compositions and processes for improving plant vigor are disclosed. | 2009-01-22 |
20090023783 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS - The invention relates to novel benzofuran derivatives, processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders | 2009-01-22 |
20090023784 | USE OF DEFERIPRONE AND METHODS TO TREAT AND/OR PREVENT FRIEDREICH ATAXIA RESULTING FROM INTRACELLULAR MISHANDLING OF IRON - A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron. | 2009-01-22 |
20090023786 | Histone Deacetylase Inhibitor Prodrugs - The present invention is directed to prodrugs of hydroxamic acid based histone deacetylase (HDAC) inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The prodrugs are acylated derivatives having increased aqueous solubility and cellular permeability as compared with the free hydroxamic acid, and are useful for inhibiting HDACs, and for selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the prodrugs of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The prodrugs of the invention are also useful in the prevention and treatment of thioredoxin (TRX)-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. | 2009-01-22 |
20090023787 | TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF - One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium complexes are also described. Another aspect of the invention relates to novel pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention. | 2009-01-22 |
20090023788 | Treatment of CRTH2-mediated diseases and conditions - The present invention provides indole derivatives that antagonize prostaglandin D | 2009-01-22 |
20090023789 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to isothiazolylidene containing compounds of Formula (I) | 2009-01-22 |
20090023790 | Microbicidal composition - Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one. | 2009-01-22 |
20090023791 | PH-dependent NMDA receptor antagonists - NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neurprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chrounic pain, vascular dementia and glioma rumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Prefebably the compounds provided herein are allosteric NMDA inhibitors. | 2009-01-22 |
20090023792 | INHIBITORS OF MELANOCYTE TYROSINASE AS TOPICAL SKIN LIGHTENERS - Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically. | 2009-01-22 |
20090023793 | INHIBITORS OF MELANOCYTE TYROSINASE AS TOPICAL SKIN LIGHTENERS - Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically. | 2009-01-22 |
20090023794 | Use of Sumoylation Inhibitors for the Treatment of Neurodegenerative Disease - The invention generally provides screening methods for the identification of therapeutic compounds useful for the treatment of a neurodegenerative disease, and related prophylactic and therapeutic compositions and methods. | 2009-01-22 |
20090023795 | Kinase Inhibitors And Methods Of Use Thereof - The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases. | 2009-01-22 |
20090023796 | Analogs of Indole-3-Carbinol Metabolites as Chemotherapeutic and Chemopreventive Agents - Novel compounds useful as chemotherapeutic and chemopreventive agents are provided. The compounds are analogs of indole-3-carbinol metabolites wherein the structures and substituents of the compounds are selected to enhance the compounds' overall efficacy, particularly with respect to therapeutic activity, oral bioavailability, long-term safety, patient tolerability, and therapeutic window. The compounds are useful not only in treatment of cancer but also in prevention of cancer. One preferred class of the novel compounds has the structure of formula (IV) | 2009-01-22 |
20090023797 | Indol-Alanine Derivatives as Selective S1P4-Agonists - The present invention relates to agonists of the S1P4 receptor, which are selective for the S1P4 receptor over one or more of the S1P1, S1P2, S1P3 or S1P5 receptors of at least 10 fold, in particular new indol-alanine derivatives of structure 1, process for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them | 2009-01-22 |
20090023798 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE - Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase. Also described herein are methods of using such HDAC inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC activity. | 2009-01-22 |
20090023799 | CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE - The present invention provides crystal forms of (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone of the formula | 2009-01-22 |
20090023800 | Cannabinoid receptor modulator - A cannabinoid receptor modulator containing a compound represented by Formula (I | 2009-01-22 |
20090023801 | INHIBITORS OF BETA AMYLOID PRODUCTION - Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R | 2009-01-22 |
20090023802 | Benzochromene Derivatives - The present invention relates to benzochromene derivatives of the formula I | 2009-01-22 |
20090023803 | Use of cacao polyphenols for treating a prostate hyperplasia, a specific cacao extract and applications - The invention relates to the use of cacao polyphenols for preventing or curing a prostate hyperplasia, to a cacao polyphenol extract which also comprises, in particular lipids and/or xanthines, and to the applications of said extract in food and pharmaceutical products for treating a prostate cancer, cognitive disorders, oxidative stress and cholesterol. | 2009-01-22 |
20090023804 | ELECTROCHEMICAL METHODS FOR REDOX CONTROL TO PRESERVE, STABILIZE AND ACTIVATE COMPOUNDS - To maximize and maintain the antioxidant or pro-oxidant state for foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations or drags, the present invention discloses methods and devices to control redox equilibrium of such preparations throughout the processing steps and storage prior to, or at, the time of administration or use. The preparations (solid or liquid form) can then be stored in a redox-controlled container, package or applicator as described in the specification. Foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations and drugs stored in reactive oxidation states can be activated and stabilized by electrical voltages applied with a small battery and electrodes designed into the applicator, container or package. | 2009-01-22 |
20090023805 | METHOD OF ADMINISTRATION - The present invention relates to the use of mycophenolic acid, a salt or prodrug thereof in immunosuppression, particularly for prevention or treatment of transplant rejection and immune-mediated and/or inflammatory diseases, wherein mycophenolic acid, the salt or the prodrug thereof is administered with an initial intensified dosage regimen. | 2009-01-22 |
20090023806 | ALUMINUM-STORAGE DISEASE IMPROVING AGENT - A safe and easy-handling method to eliminate aluminum, which can easily accumulate in a dialysis patient body, in the course of a dialysis treatment and a dialysate used in the above method to eliminate aluminum ions from blood and tissues in the body are provided. A method to eliminate aluminum from a dialysis patient body characterized in that a dialysate mixed with aluminum complexing agents allows formation of complexes with aluminum to excrete aluminum in the form of aluminum complexes into the dialysis drain fluid is also provided. More specifically, the above-mentioned method to eliminate aluminum from the body employs preferably citric acid as an aluminum complexing agent, and the dialysate comprises general dialysate components and 1.7-2.4 mEq/L of citric acid as an aluminum complexing agent. | 2009-01-22 |
20090023807 | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R | 2009-01-22 |
20090023808 | Production and Purification of Esters of Polyunsaturated Fatty Acids - The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation. | 2009-01-22 |
20090023809 | HYDROGEN CYANAMIDE PESTICIDE FORMULATIONS - Agricultural crops are protected from the growth of undesirable vegetation as well as nematode and insect infestations, by the application of hydrogen cyanamide in combination with a short-chain, water-soluble monocarboxylic acid, with improved pesticidal effect. | 2009-01-22 |
20090023810 | METHODS OF TRANSLATION AND/OR INFLAMMATION BLOCKADE - The present invention relates to a method of translation or inflammatory response blockade by using a compound that binds to eIF4A, which is the 264 | 2009-01-22 |
20090023811 | Biphenyl compound selective agonists of gamma RAR receptors - Biphenyl compounds having the formula (I): | 2009-01-22 |
20090023812 | N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES - The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds. | 2009-01-22 |
20090023813 | Diphenyl Urea Derivatives - The invention relates to novel specifically trifluoromethyl and halogen substituted 1,3-diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects like the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives. | 2009-01-22 |
20090023814 | COMPOSITIONS AND METHODS HAVING MT1 RECEPTOR ACTIVITY - The present invention is directed to compositions and to methods comprising a composition comprising a therapeutically effective amount of a pharmaceutically active agent such as (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats and/or manages at least one condition having MT1 receptor activity and releases the pharmaceutically active agent, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a primary activity on the MT1 receptor such as, exhibiting at least five times more activity on the MT1 receptor compared with the MT2 receptor. | 2009-01-22 |
20090023815 | PROCESS FOR THE RECOVERY OF TYROSOL AND HYDROXYTYROSOL FROM OIL MILL WASTEWATERS AND CATALYTIC OXIDATION METHOD IN ORDER TO CONVERT TYROSOL IN HYDROXYTYROSOL - A process for preparing Tyrosol and/or Hydroxytyrosol from oil mill wastewaters.
| 2009-01-22 |
20090023816 | PROCESS FOR MAKING A SOLID COMPOUND BY PRECIPITATION, SUSPENSIONS OF SOLID IN LIQUIDS AND SOLIDS OBTAINED BY THE PROCESS AND THEIR USE AS ADDITIVES - Process for making a solid compound by precipitation, using a high intensity mixing reactor and comprising the steps of (A) introducing a first fluid material containing a first reactant and a second fluid material containing a second reactant into said reactor, in order to obtain a mixed fluid, in order to cause the first reactant to react with the second reactant to form a solid compound by precipitation in the mixed fluid; (B) withdrawing the mixed fluid containing the precipitated solid obtained in step (A) from the reactor, and; (C) optionally separating the precipitated solid compound from at least one fraction of the mixed fluid. | 2009-01-22 |
20090023817 | Aqueous compositions comprising alkyl polyethylene glycol ether sulfates - The present invention provides aqueous compositions comprising, as well as water, 75% to 90% by weight of alkyl polyethylene glycol ether sulfates which are a mixture of compounds of formula (1) | 2009-01-22 |
20090023818 | Wetting Agent Based on a Mixture of Monoesters and Diesters of Butylene Glycol - Pigment wetting agent contains a mixture of monoesters and diesters of butylene glycol and fatty acids. | 2009-01-22 |
20090023819 | Use of an Artificial Sweetener to Enhance Absorption of Nicotine - The present invention relates to increased absorption of nicotine over the prior art. In particular the absorption of nicotine is enhanced after administration of a composition containing nicotine and a sweetener such as an artificial sweetener like saccharin to the oral mucosa in the form of a spray. | 2009-01-22 |